Atosiban Impurity E is a related peptide variant that forms during atosiban synthesis or storage. Structural deviations adjust disulfide geometry, hydrophobic packing, and chromatographic behavior. Researchers employ it as a reference to refine impurity profiles and degradation mapping. Applications include analytical-method validation, process understanding, and structural-variant characterization.
CAT No: Z10-101-220
Synonyms/Alias:Atosiban impurity E,Mpr-DTyr(Et)-Ile-Thr-Asn-Cys-Pro-Cyclo(Orn)(Mpr1&Cys6 bridge);
Atosiban impurity E is a structurally defined organic compound that is recognized as a process-related impurity associated with the synthesis and analysis of the peptide drug atosiban. As a chemically characterized byproduct arising during the manufacturing or degradation of atosiban, impurity E is of significant interest in pharmaceutical research and quality control. Its presence, structural features, and behavior provide valuable insight into the stability, purity, and synthetic pathways of peptide-based therapeutics. The study of such impurities is essential for comprehensive characterization of active pharmaceutical ingredients (APIs), supporting both regulatory compliance and the advancement of analytical methodologies within the peptide research field.
Impurity profiling: The identification and quantification of process-related impurities like impurity E are critical components of impurity profiling in pharmaceutical development. Researchers utilize this compound as a reference standard in analytical method development and validation, enabling accurate detection and quantification of trace impurities in atosiban formulations. By establishing the presence and concentration of impurity E, laboratories can ensure the integrity and safety of peptide-based drug substances through robust quality control protocols.
Analytical method development: The availability of defined impurities such as impurity E supports the advancement of sensitive and selective analytical techniques, including high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Scientists employ this compound to optimize separation conditions, calibrate detection systems, and assess method specificity in the presence of structurally similar byproducts. Its inclusion in method validation procedures enhances the reliability of impurity detection and quantification in complex peptide matrices.
Stability studies: Impurity E plays a vital role in forced degradation and stability-indicating studies for atosiban and related peptides. By monitoring the formation and behavior of this compound under various stress conditions, researchers can elucidate degradation pathways, assess the chemical stability of peptide formulations, and identify potential risks associated with storage or handling. Such studies contribute to the design of robust formulations with improved shelf-life and safety profiles.
Synthetic process optimization: The occurrence and characterization of impurity E provide valuable feedback for process chemists seeking to refine peptide synthesis protocols. By understanding the mechanistic origins and formation routes of this specific impurity, researchers can modify reaction conditions, purification strategies, or reagent selection to minimize its generation. This iterative optimization enhances the overall efficiency, yield, and purity of peptide manufacturing processes.
Reference material for regulatory submissions: Well-characterized impurities such as impurity E are frequently required as reference materials during regulatory submissions and dossier preparation for peptide-based pharmaceuticals. Their inclusion supports the comprehensive documentation of impurity profiles, facilitates comparative studies across manufacturing batches, and aids in meeting stringent regulatory expectations for impurity identification and control. The use of authentic reference standards underpins the scientific rigor and transparency demanded in the development and approval of high-quality peptide therapeutics.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More